Mechanisms and treatment of cancer cachexia

被引:37
作者
Argiles, J. M. [1 ,2 ]
Lopez-Soriano, F. J. [1 ,2 ]
Busquets, S. [1 ,2 ]
机构
[1] Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Canc Res Grp, E-08028 Barcelona, Spain
[2] Univ Barcelona, Inst Biomed, E-08028 Barcelona, Spain
关键词
Wasting; Cancer; Anorexia; Nutraceuticals; Drugs;
D O I
10.1016/j.numecd.2012.04.011
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
According to a recent consensus, cachexia is a complex metabolic syndrome associated with underlying illness and characterised by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss. Cachexia occurs in the majority of terminal cancer patients and it is responsible for the deaths of 22% of cancer patients. Although body weight is, indeed, an important factor to be taken into consideration in any cachexia treatment, body composition, physical performance and quality of life should be monitored. From the results presented here, one can speculate that a single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful. The objectives of any therapeutical combination are two: an anticatabolic aim directed towards both fat and muscle catabolism and an anabolic objective leading to the synthesis of macromolecules such as contractile proteins. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:S19 / S24
页数:6
相关论文
共 51 条
[1]
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH [J].
Anker, SD ;
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 86 (2-3) :123-130
[2]
EFFECT OF OMEGA-3-FATTY-ACIDS ON RECTAL MUCOSAL CELL-PROLIFERATION IN SUBJECTS AT RISK FOR COLON CANCER [J].
ANTI, M ;
MARRA, G ;
ARMELAO, F ;
BARTOLI, GM ;
FICARELLI, R ;
PERCESEPE, A ;
DEVITIS, I ;
MARIA, G ;
SOFO, L ;
RAPACCINI, GL ;
GENTILONI, N ;
PICCIONI, E ;
MIGGIANO, G .
GASTROENTEROLOGY, 1992, 103 (03) :883-891
[3]
Novel approaches to the treatment of cachexia [J].
Argiles, Josep M. ;
Lopez-Soriano, Franco J. ;
Busquets, Silvia .
DRUG DISCOVERY TODAY, 2008, 13 (1-2) :73-78
[4]
Argiles Josep M, 2007, Curr Opin Support Palliat Care, V1, P293, DOI 10.1097/SPC.0b013e3282f34738
[5]
Selective androgen receptor modulators as function promoting therapies [J].
Bhasin, Shalender ;
Jasuja, Ravi .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2009, 12 (03) :232-240
[6]
BRUERA E, 1990, CANCER-AM CANCER SOC, V66, P1279, DOI 10.1002/1097-0142(19900915)66:6<1279::AID-CNCR2820660630>3.0.CO
[7]
2-R
[8]
Busquets S, 2005, INT J MOL MED, V16, P471
[9]
Anticachectic effects of formoterol:: A drug for potential treatment of muscle wasting [J].
Busquets, S ;
Figueras, MT ;
Fuster, G ;
Almendro, V ;
Moore-Carrasco, R ;
Ametller, E ;
Argilés, JM ;
López-Soriano, FJ .
CANCER RESEARCH, 2004, 64 (18) :6725-6731
[10]
Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia [J].
Busquets, Silvia ;
Serpe, Roberto ;
Sirisi, Sonia ;
Toledo, Miriam ;
Coutinho, Joana ;
Martinez, Raquel ;
Orpi, Marcel ;
Lopez-Soriano, Francisco J. ;
Argiles, Josep M. .
CLINICAL NUTRITION, 2010, 29 (06) :733-737